News headlines about Penumbra (NYSE:PEN) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Penumbra earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.6401725940875 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Robert D. Evans Sells 10,000 Shares of Penumbra Inc (PEN) Stock (americanbankingnews.com)
- What Should We Expect From Penumbra Inc’s (NYSE:PEN) Earnings In The Year Ahead? (finance.yahoo.com)
- Penumbra Inc (PEN) Expected to Announce Quarterly Sales of $92.57 Million (americanbankingnews.com)
- Neurovascular Devices Market is Estimated to grow at a CAGR of 8.8% till 2023 (medgadget.com)
- Form 4 Penumbra Inc For: Mar 05 Filed by: Rothman Lynn (streetinsider.com)
Several research firms have commented on PEN. Wells Fargo & Co boosted their target price on Penumbra to $138.00 and gave the company an “outperform” rating in a research note on Tuesday. BMO Capital Markets boosted their target price on Penumbra from $110.00 to $115.00 and gave the company a “market perform” rating in a research note on Wednesday, February 28th. Zacks Investment Research cut Penumbra from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Canaccord Genuity reiterated a “buy” rating and set a $125.00 price objective (up previously from $113.00) on shares of Penumbra in a research note on Wednesday, February 28th. Finally, William Blair assumed coverage on Penumbra in a research note on Wednesday, February 21st. They set an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Penumbra presently has an average rating of “Hold” and an average price target of $126.00.
In other news, EVP Robert D. Evans sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $89.89, for a total transaction of $3,595,600.00. Following the sale, the executive vice president now owns 11,704 shares in the company, valued at approximately $1,052,072.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Thomas Wilder sold 345 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $91.15, for a total value of $31,446.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 94,345 shares of company stock worth $8,939,204. Company insiders own 13.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/15/penumbra-pen-getting-somewhat-positive-press-coverage-report-shows/2036141.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.